Pharmaceuticals, Biotechnology and Life Sciences
Novartis on Friday said that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of Rydapt (midostaurin) for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive.
Pfizer has decided to cancel listing of its stocks from the UK listing Authority List. The company said on Wednesday it also cancels trading on the main London Stock Exchange market.
Innate Pharma’s “EffiKIR” trial of lirilumab as a single agent maintenance treatment in elderly patients with acute myeloid leukemia (AML) in first complete remission, did not meet its primary efficacy endpoint of leukemia-free survival (LFS).
Indian drugmaker Natco Pharma has gotten the approval from the U.S. regulator for generic version of Teva’s leukemia treatment Trenda (Bendamustine Hydrochloride powder for Injection).
Celyad advances first NKG2D CAR T-Cell Phase I study